WithdrawnPhase 1

Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%

Stopped: Unable to recruit participants from recruiting sites.

Canada0Started 2012-06

Plain-language summary

The purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the progression or improves recovery of patients who are randomly assigned to treatment versus standard of care.

Who can participate

Age range

41 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>40 * Sudden, painless monocular vision loss with edema of the optic disc * Clinical diagnosis is Non-Arteritic Anterior Ischemic Optic Neuropathy * Relative Afferent Pupil Defect (RAPD) at first study visit Exclusion Criteria: * Onset of vision loss \>48 hours from time of enrollment * History of Asthma or COPD * History of Heart Block or Sinus Bradycardia * Allergy to any beta blocker * History of Multiple Sclerosis or optic neuropathy * Active Ocular Inflammation on examination * Currently being treated for Cancer or systemic vasculitis * History of Glaucoma or use of medications that lower IOP * Symptomatic cataract, retinopathy, macular disease or amblyopia in the symptomatic eye * IOP of \<10 at baseline * Ocular surgery in past three months * Women who are pregnant, breast-feeding or may become pregnant * Inability to provide informed consent or follow up at three months * Currently enrolled in any other study drug trial or previously enrolled in this study

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Recruitment Rate of patients during the one year study to assess feasibility of a larger study

Timeframe: 12 months

Number of patients with adverse events

Timeframe: 12 months

Trial details

NCT IDNCT01607671

SponsorFraser Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-11

View on ClinicalTrials.gov More Optic Neuropathy, Ischemic trials